Matches in SemOpenAlex for { <https://semopenalex.org/work/W2439732947> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2439732947 endingPage "31" @default.
- W2439732947 startingPage "2625" @default.
- W2439732947 abstract "Cyclooxygenase (COX), also referred to as prostaglandin endoperoxide synthase, is a key enzyme in the conversion of arachidonic acid to prostaglandins and other eicosanoids. Epidemiologic, animal and in vitro observations show a positive correlation between the expression of COX (especially COX-2) and colonic cancer development, growth and apoptosis. Constitutive expression of COX-2 in human pancreatic cancer cells was recently reported. To evaluate the potential role of COX in pancreatic cancer, RT-PCR was used to determine the constitutive expression of COX-2 in four pancreatic cancer cell lines. MiaPaCa2, PANC-1, HPAF, ASPC-1. The effect of COX blockade with either the general COX inhibitor, indomethacin, or the specific COX-2 inhibitor, NS-398, on [3H]-thymidine incorporation and cell number was investigated in these four pancreatic cancer cell lines. In addition, the effects of these COX inhibitors on pancreatic cancer cell apoptosis was evaluated by DNA propidium iodide staining and the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay. All four human pancreatic cancer cell lines expressed COX-2 and their proliferation was concentration- and time-dependently inhibited by both indomethacin andNS398. Substantial apoptosis was also induced by treatment of pancreatic cancer cells with either indomethacin or NS398, as indicated by both DNA propidium iodide staining and the TUNEL assay. Furthermore, indomethacin and NS398 were equipotent for growth inhibition and induction of apoptosis, indicating that eicosanoid synthesis via COX-2 is involved in pancreatic cancer cell proliferation and survival. In conclusion, these findings suggest that the COX pathway, especially COX-2, contributes to the growth and apoptosis of pancreatic cancer. Specific COX-2 inhibitors are likely to be valuable for the treatment and prevention of this deadly cancer." @default.
- W2439732947 created "2016-06-24" @default.
- W2439732947 creator A5000233610 @default.
- W2439732947 creator A5038117732 @default.
- W2439732947 creator A5046088910 @default.
- W2439732947 date "2000-08-23" @default.
- W2439732947 modified "2023-09-22" @default.
- W2439732947 title "Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells." @default.
- W2439732947 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10953335" @default.
- W2439732947 hasPublicationYear "2000" @default.
- W2439732947 type Work @default.
- W2439732947 sameAs 2439732947 @default.
- W2439732947 citedByCount "44" @default.
- W2439732947 countsByYear W24397329472012 @default.
- W2439732947 countsByYear W24397329472015 @default.
- W2439732947 countsByYear W24397329472016 @default.
- W2439732947 countsByYear W24397329472021 @default.
- W2439732947 crossrefType "journal-article" @default.
- W2439732947 hasAuthorship W2439732947A5000233610 @default.
- W2439732947 hasAuthorship W2439732947A5038117732 @default.
- W2439732947 hasAuthorship W2439732947A5046088910 @default.
- W2439732947 hasConcept C121608353 @default.
- W2439732947 hasConcept C126322002 @default.
- W2439732947 hasConcept C134018914 @default.
- W2439732947 hasConcept C181199279 @default.
- W2439732947 hasConcept C190283241 @default.
- W2439732947 hasConcept C196795494 @default.
- W2439732947 hasConcept C2775934118 @default.
- W2439732947 hasConcept C2779689624 @default.
- W2439732947 hasConcept C2780210213 @default.
- W2439732947 hasConcept C31573885 @default.
- W2439732947 hasConcept C502942594 @default.
- W2439732947 hasConcept C55493867 @default.
- W2439732947 hasConcept C62112901 @default.
- W2439732947 hasConcept C71924100 @default.
- W2439732947 hasConcept C86803240 @default.
- W2439732947 hasConcept C96232424 @default.
- W2439732947 hasConceptScore W2439732947C121608353 @default.
- W2439732947 hasConceptScore W2439732947C126322002 @default.
- W2439732947 hasConceptScore W2439732947C134018914 @default.
- W2439732947 hasConceptScore W2439732947C181199279 @default.
- W2439732947 hasConceptScore W2439732947C190283241 @default.
- W2439732947 hasConceptScore W2439732947C196795494 @default.
- W2439732947 hasConceptScore W2439732947C2775934118 @default.
- W2439732947 hasConceptScore W2439732947C2779689624 @default.
- W2439732947 hasConceptScore W2439732947C2780210213 @default.
- W2439732947 hasConceptScore W2439732947C31573885 @default.
- W2439732947 hasConceptScore W2439732947C502942594 @default.
- W2439732947 hasConceptScore W2439732947C55493867 @default.
- W2439732947 hasConceptScore W2439732947C62112901 @default.
- W2439732947 hasConceptScore W2439732947C71924100 @default.
- W2439732947 hasConceptScore W2439732947C86803240 @default.
- W2439732947 hasConceptScore W2439732947C96232424 @default.
- W2439732947 hasIssue "4" @default.
- W2439732947 hasLocation W24397329471 @default.
- W2439732947 hasOpenAccess W2439732947 @default.
- W2439732947 hasPrimaryLocation W24397329471 @default.
- W2439732947 hasRelatedWork W1906345089 @default.
- W2439732947 hasRelatedWork W1971995740 @default.
- W2439732947 hasRelatedWork W1986139333 @default.
- W2439732947 hasRelatedWork W2058494224 @default.
- W2439732947 hasRelatedWork W2074343580 @default.
- W2439732947 hasRelatedWork W2119372198 @default.
- W2439732947 hasRelatedWork W2356526771 @default.
- W2439732947 hasRelatedWork W2366145050 @default.
- W2439732947 hasRelatedWork W2385348096 @default.
- W2439732947 hasRelatedWork W2386169131 @default.
- W2439732947 hasVolume "20" @default.
- W2439732947 isParatext "false" @default.
- W2439732947 isRetracted "false" @default.
- W2439732947 magId "2439732947" @default.
- W2439732947 workType "article" @default.